scholarly journals Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis

2021 ◽  
Author(s):  
Jack D Sobel ◽  
Paul Nyirjesy
Keyword(s):  
Treatment Option ◽  
Symptom Control ◽  
Vulvovaginal Candidiasis ◽  
High Rate ◽  
Tolerability Profile ◽  
Cytochrome P450 Enzyme ◽  
Recurrent Vulvovaginal Candidiasis ◽  
Development Of Resistance ◽  
P450 Enzyme

Recurrent vulvovaginal candidiasis (RVVC) has significant disease, financial and quality-of-life burdens, affects women from all strata of society worldwide, and lacks an approved therapeutic solution. Fluconazole emerged in 2004 as an antifungal for RVVC; it provides symptom control and has been accepted worldwide as a first-line treatment. Its limitations include the development of resistance and a high rate of vulvovaginal candidiasis recurrence after therapy cessation. There is now an improved treatment option on the horizon: oteseconazole – a novel, oral, selective fungal cytochrome P450 enzyme 51 inhibitor, designed to avoid off-target toxicities. In clinical studies to date, oteseconazole has demonstrated impressive efficacy, a positive tolerability profile and hope for a superior RVVC treatment option.

scholarly journals Recurrent Vulvovaginal Candidiasis

2021 ◽  
Vol 5 (5) ◽  
pp. 474-483
Author(s):  
Cyntya Sari Sovianti ◽  
Mutia Devi
Keyword(s):  
Quality Of Life ◽  
Topical Therapy ◽  
Predisposing Factors ◽  
Vulvovaginal Candidiasis ◽  
Suppressive Therapy ◽  
Recurrent Vulvovaginal Candidiasis ◽  
Candida Sp ◽  
Microbiological Examination ◽  
Culture Negative

Vulvovaginal candidiasis is a common fungal infection caused by Candida Sp, especially Candida albicans. Recurrent vulvovaginal candidiasis was defined as the occurrence of four or more episodes of vulvovaginal candidiasis ​​in 12 months period. As many as 9% of women from various populations have recurrent vulvovaginal candidiasis. Vulvovaginal candidiasis affects the quality of life, mental health, and sexual activity. There are many predisposing factors that caused recurrent vulvovaginal candidiasis, such as genetics, host, habit, idiopathic and non-albican candida microbes. Management of recurrent vulvovaginal candidiasis includes elimination of predisposing factors; mycological culture diagnosis and identification of specific Candida species; followed by microbiological examination to confirm the sensitivity of the azole group to Candida sp. Further, oral, or topical therapy should be continued until the patient is asymptomatic and culture-negative. Patients should receive induction therapy followed by maintenance suppressive therapy for six months.

scholarly journals Recurrent Vulvovaginal Candidiasis

2021 ◽  
Vol 5 (3) ◽  
pp. 498-507
Author(s):  
Cyntya Sari Sovianti ◽  
Mutia Devi
Keyword(s):  
Quality Of Life ◽  
Mental Health ◽  
Topical Therapy ◽  
Predisposing Factors ◽  
Vulvovaginal Candidiasis ◽  
Suppressive Therapy ◽  
Recurrent Vulvovaginal Candidiasis ◽  
Candida Sp ◽  
Culture Negative

Vulvovaginal candidiasis is a common fungal infection caused by Candida Sp,especially Candida albicans. Recurrent vulvovaginal candidiasis was defined asthe occurrence of four or more episodes of vulvovaginal candidiasis in 12 monthsperiod. As many as 9% of women from various populations have recurrentvulvovaginal candidiasis. Vulvovaginal candidiasis affects the quality of life,mental health, and sexual activity. There are many predisposing factors thatcaused recurrent vulvovaginal candidiasis, such as genetics, host, habit,idiopathic and non-albican candida microbes. Management of recurrentvulvovaginal candidiasis includes elimination of predisposing factors; mycologicalculture diagnosis and identification of specific Candida species; followed bymicrobiological examination to confirm the sensitivity of the azole group toCandida sp. Further, oral, or topical therapy should be continued until the patientis asymptomatic and culture-negative. Patients should receive induction therapyfollowed by maintenance suppressive therapy for six months.

Influence of recurrent vulvovaginal candidiasis on quality of life issues

2019 ◽  
Vol 300 (3) ◽  
pp. 647-650 ◽  
Author(s):  
Eiko I. Fukazawa ◽  
Steven S. Witkin ◽  
Renata Robial ◽  
João G. Vinagre ◽  
Edmund C. Baracat ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Vulvovaginal Candidiasis ◽  
Recurrent Vulvovaginal Candidiasis ◽  
Life Issues

scholarly journals Use of fluconazole in women of reproductive age with vulvovaginal candidiasis

2018 ◽  
pp. 96-102
Author(s):  
E. A. Mezhevitinova ◽  
P. R. Abakarova ◽  
Sh. M. Pogosyan
Keyword(s):  
Quality Of Life ◽  
Vulvovaginal Candidiasis ◽  
Reproductive Age ◽  
Common Disease ◽  
Women Of Reproductive Age ◽  
Recurrent Vulvovaginal Candidiasis ◽  
Group I ◽  
Relapse Therapy

Topicality: vulvovaginal candidiasis (VVC) is a common disease caused by the infectious damage of the vulva and vagina by yeast-like fungi from Candida genus. According to the literature, a VVC episode occurs in 75% of women, and 5-8% of them get a recurring course of the disease. Frequent recurrences of the disease may result in the psychosexual disorder and reduce the women’s quality of life and recurrent vulvovaginal candidiasis (VVC) therapy is still a very difficult task.Purpose of the study: evaluate the efficacy of fluconazole (150 mg) in acute and recurrent vulvovaginal candidiasis.Materials and methods:A total of 89 women of reproductive age with acute and recurrent HCV were enrolled in the study, which were subdivided into 2 groups: the first group included women with acute vulvovaginal candidiasis (AVVC) (n = 51), and the second group - women with recurrent vulvovaginal candidiasis (RVVC) (n = 38). The Group I (AVVC) received fluconazole 150 mg once. Depending on the prescribed therapy, the second group (RVVC) was subdivided into two subgroups: patients in the IIa subgroup received fluconazole 150 mg intravenously, three times, at intervals of 2 days, and women in the IIb subgroup received fluconazole 150 mg for a period of 6 months in addition to the three-fold intake of fluconazole weekly. The follow-up period was 6 months after the end of therapy, during which the frequency of VVC recurrence and the effectiveness of the therapy was evaluated.Results of the study: our data showed that all patients with acute VVC had a discontinuation of symptoms of the disease and a normalization of laboratory parameters after treatment with fluconazole, and after the anti-relapse therapy course the incidence of VVC recurrences was significantly lower compared to the period before anti-relapse therapy (p = 0.038). It was shown that all the investigated strains of C. albicans (100%) were sensitive to fluconazole, and resistance was detected only in 1 strain of C. glabrata and 1 strain of C. krusei. 

scholarly journals A High Rate of Recurrent Vulvovaginal Candidiasis and Therapeutic Failure of Azole Derivatives Among Iranian Women

2021 ◽  
Vol 12 ◽  
Author(s):  
Amir Arastehfar ◽  
Melika Laal Kargar ◽  
Shahla Roudbar Mohammadi ◽  
Maryam Roudbary ◽  
Nayereh Ghods ◽  
...  
Keyword(s):  
Fungal Infections ◽  
Therapeutic Failure ◽  
Vulvovaginal Candidiasis ◽  
High Rate ◽  
Iranian Women ◽  
Related Factors ◽  
Therapeutic Success ◽  
Over The Counter ◽  
Factors Affecting ◽  
Recurrent Vulvovaginal Candidiasis

Recurrent vulvovaginal candidiasis (RVVC) is one of the most prevalent fungal infections in humans, especially in developing countries; however, it is underestimated and regarded as an easy-to-treat condition. RVVC may be caused by dysbiosis of the microbiome and other host-, pathogen-, and antifungal drug-related factors. Although multiple studies on host-related factors affecting the outcome have been conducted, such studies on Candida-derived factors and their association with RVVC are lacking. Thus, fluconazole-tolerant (FLZT) isolates may cause fluconazole therapeutic failure (FTF), but this concept has not been assessed in the context of Candida-associated vaginitis. Iran is among the countries with the highest burden of RVVC; however, comprehensive studies detailing the clinical and microbiological features of this complication are scarce. Therefore, we conducted a 1-year prospective study with the aim to determine the RVVC burden among women referred to a gynecology hospital in Tehran, the association of the previous exposure to clotrimazole and fluconazole with the emergence of FLZT and fluconazole-resistant (FLZR) Candida isolates, and the relevance of these phenotypes to FTF. The results indicated that about 53% of the patients (43/81) experienced RVVC. Candida albicans and C. glabrata constituted approximately 90% of the yeast isolates (72 patients). Except for one FLZT C. tropicalis isolate, FLZR and FLZT phenotypes were detected exclusively in patients with RVVC; among them, 27.9% (12/43) harbored FLZR strains. C. albicans constituted 81.2% of FLZR (13/16) and 100% of the FLZT (13/13) isolates, respectively, and both phenotypes were likely responsible for FTF, which was also observed among patients with RVVC infected with fluconazole-susceptible isolates. Thus, FTF could be due to host-, drug-, and pathogen-related characteristics. Our study indicates that FLZT and FLZR isolates may arise following the exposure to over-the-counter (OTC) topical azole (clotrimazole) and that both phenotypes can cause FTF. Therefore, the widespread use of OTC azoles can influence fluconazole therapeutic success, highlighting the necessity of controlling the use of weak topical antifungals among Iranian women.

scholarly journals Recurrent Vulvovaginal Candidiasis: An Immunological Perspective

2020 ◽  
Vol 8 (2) ◽  
pp. 144 ◽  
Author(s):  
Diletta Rosati ◽  
Mariolina Bruno ◽  
Martin Jaeger ◽  
Jaap ten Oever ◽  
Mihai G. Netea
Keyword(s):  
Fungal Infections ◽  
Protective Role ◽  
Vulvovaginal Candidiasis ◽  
Candida Colonization ◽  
Childbearing Age ◽  
Recurrent Vulvovaginal Candidiasis ◽  
Long Time ◽  
Different Populations ◽  
New Hypothesis

Vulvovaginal candidiasis (VVC) is a widespread vaginal infection primarily caused by Candida albicans. VVC affects up to 75% of women of childbearing age once in their life, and up to 9% of women in different populations experience more than three episodes per year, which is defined as recurrent vulvovaginal candidiasis (RVVC). RVVC results in diminished quality of life as well as increased associated healthcare costs. For a long time, VVC has been considered the outcome of inadequate host defenses against Candida colonization, as in the case of primary immunodeficiencies associated with persistent fungal infections and insufficient clearance. Intensive research in recent decades has led to a new hypothesis that points toward a local mucosal overreaction of the immune system rather than a defective host response to Candida colonization. This review provides an overview of the current understanding of the host immune response in VVC pathogenesis and suggests that a tightly regulated fungus–host–microbiota interplay might exert a protective role against recurrent Candida infections.

scholarly journals Optimization of treatment of recurrent vulvovaginal candidiasis

2019 ◽  
Vol 2 (14) ◽  
pp. 27-30
Author(s):  
L. V. Tkachenko ◽  
N. I. Sviridova ◽  
L. N. Bogatyryova ◽  
I. A. Gritsenko
Keyword(s):  
Quality Of Life ◽  
Menstrual Cycle ◽  
Comparison Group ◽  
Vulvovaginal Candidiasis ◽  
Menstrual Cycles ◽  
Recurrent Vulvovaginal Candidiasis ◽  
The Mean ◽  
Efficacy Of Treatment ◽  
Consecutive Cycle

The purpose of the study was to evaluate the efficacy of treatment of recurrent drug Orungamin depending on the time of occurrence of relapse.Material and methods. 62 women with recurrent candida vulvovaginit is were examined and treated. The mean age of the patients was 35.6 ± 0.7 years. The main group consisted of 32 patients who in the premenstrual period 5 days before the expected date of menstruation were prescribed Orungamin 1 capsule (100 mg) twice a day (200 mg) for 3 days during three consecutive menstrual cycles. The comparison group included women receiving Orungamin three consecutive cycle 3 day 1 capsule (100 mg) 2 times a day, without regard to days of the menstrual cycle.Results. Therapy with Orungamin 100 mg twice a day during the premenstrual period not only helped to increase the effectiveness of the treatment of relapses, but also the quality of life of patients.

Sign in / Sign up

Export Citation Format

Share Document